bosutinib (Bosulif, SKI-606)

From Aaushi
Jump to navigation Jump to search

Indications

Dosage

  • 500 mg PO QD with food until disease progression or patient intolerance
  • 200 mg/day (ADPKD)

Tabs: 100 mg, 500 mg

Adverse effects

Mechanism of action

More general terms

References

  1. Wikipedia: Bosutinib http://en.wikipedia.org/wiki/Bosutinib
  2. FDA Approval for Bosutinib, September 4, 2012 National Cancer Institute http://www.cancer.gov/cancertopics/druginfo/fda-bosutinib
  3. Cortes JE et al Bosutinib Versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia: Results From the BELA Trial. J Clin Oncol. 2012 Oct 1;30(28):3486-92. Epub 2012 Sep 4. PMID: https://www.ncbi.nlm.nih.gov/pubmed/22949154
  4. 4.0 4.1 Minerd J Cancer Drug May Help in ADPKD. Bosutinib slowed kidney enlargement in phase II study. MedPage Today. August 24, 2017 https://www.medpagetoday.com/Nephrology/GeneralNephrology/67482
    Tesar V, Ciechanowski K, Pei Y al Bosutinib versus placebo for autosomal dominant polycystic kidney disease J Am Soc Nephrol. 2017 Aug 24. pii: ASN.2016111232. PMID: https://www.ncbi.nlm.nih.gov/pubmed/28838955

Database